51
|
Walpurgis K, Kohler M, Thomas A, Wenzel F, Geyer H, Schänzer W, Thevis M. Validated hemoglobin-depletion approach for red blood cell lysate proteome analysis by means of 2D PAGE and Orbitrap MS. Electrophoresis 2012; 33:2537-45. [DOI: 10.1002/elps.201200151] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
52
|
Wenzel F, Gettmann T, Zimmermann N, Giers G. Alterations of serum erythropoietin and thrombopoietin levels in patients undergoing Coronary Artery Bypass Grafting (CABG). Clin Hemorheol Microcirc 2012; 49:399-406. [PMID: 22214710 DOI: 10.3233/ch-2011-1489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
INTRODUCTION The hormones erythropoietin (EPO) and thrombopoietin (TPO) are main regulators of erythro- and thrombopoiesis. Cell loss caused by operative procedures may alter serum levels of the hormones, resulting in well known phenomenons like reactice thrombocytosis. MATERIAL AND METHODS Blood samples from 10 patients (mean age 63 ± 9 years) were obtained before and at day 1, 5 and 10 after coronary artery bypass grafting (CABG). EPO and TPO levels were determined by commercially available ELISA-Kits (R&D Systems, Germany). In addition, platelet count (PC) and hemoglobin concentration (Hb) were determined. RESULTS Prior to CABG, EPO (13.2 ± 8.2 mU/mL), TPO (189 ± 52 pg/mL), Hb (8.8 ± 1.1 mmol/L) and PC (254 ± 121/nL) were within a normal range. At day 1 after surgery, Hb and PC were significantly decreased to 6.6 ± 0.9 mmol/L and 138 ± 70/nL. In contrast, EPO and TPO were significantly elevated to 32 ± 18 mU/mL and 336 ± 96 pg/mL, respectively, in spite of hemodilution. In particular, TPO elevation was followed by a significant increase in PC (342 ± 144/nL) at day 10 after surgery compared to preoperative values. CONCLUSIONS Appropriate to the decrease in hemoglobin concentration and platelet count, clear alterations of serum erythropoietin and thrombopoietin levels could postoperatively be observed. EPO levels showed an inverse correlation to hemoglobin concentrations, whereas a disturbed thrombopoietin feedback mechanism resulted in the phenomenon of reactive thrombocytosis.
Collapse
|
53
|
Wenzel F, Hohlfeld T, Giers G. Soluble CD40L release as test for functional platelet loss. Clin Lab 2012; 58:337-342. [PMID: 22582510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND During platelet storage, alterations of the platelet function, 'platelet storage lesion', can be observed resulting in a reduced platelet viability. The release of soluble CD40 ligand (sCD40L) by platelets reflects different aspects of platelet metabolism and activity. Therefore, we used the sCD40L release to test for functional platelet loss in platelet products during storage in comparison to the formation of thromboxane (TXB2). METHODS On day 1, 3, and 5 in single donor apheresis platelet products (n = 8) under routine storage conditions, sCD40L (measured by ELISA) and TXB2 (measured by RIA) were determined after platelet stimulation (recalcification and clot formation). Results were related to a therapeutic unit (TU = 2 x 10*11 platelets). RESULTS In platelet-rich plasma of the donors, sCD40L release was 42.5 +/- 7.1 ng/TU and TXB2 formation 2,183 +/- 576 ng/TU. On day 1, 3, and 5 sCD40L release was reduced to 95%, 64%, and 57% and TXB2 formation to 92%, 80%, and 65% of the respective control values. CONCLUSIONS In single donor apheresis PCs, sCD40L release and TXB2 formation showed a comparable course over storage time and were reduced to about 60% of the respective control values after a storage period of 5 days. These findings are in line with literature data indicating that a functional platelet loss of about 30% will occur after 5 days of storage. Overall, sCD40L release could be easily induced by recalcification and clot formation and can be used as a marker for functional platelet loss.
Collapse
|
54
|
Wenzel F, Günther W, Baertl A, Gruber W, Sorg RV, Haas R, Giers G. Platelet transfusion alters CD40L blood level and release capacity in patients suffering from thrombocytopenia. Transfusion 2011; 52:1213-20. [PMID: 22082313 DOI: 10.1111/j.1537-2995.2011.03438.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Platelet (PLT)-derived cytokines, such as soluble CD40 ligand (sCD40L), play an important role in the development of adverse transfusion reactions associated with the administration of PLT products. In this study, we determined sCD40L concentration and release capacity in patients with thrombocytopenia before and after receiving a PLT transfusion. STUDY DESIGN AND METHODS The study included 12 patients suffering from chemotherapy-induced thrombocytopenia. sCD40L levels and release capacity were measured in plasma samples of the patients before and after PLT administration as well as in the respective plateletpheresis concentrates by enzyme-linked immunosorbent assay. Sixteen healthy blood donors served as a control group. RESULTS In PLT concentrates, elevated sCD40L levels (2567±134 pg/mL) were observed in comparison to plasma sCD40L levels in controls (238.4±35.3 pg/mL). sCD40L plasma concentration of patients with thrombocytopenia was significantly reduced (86.3±16.7 pg/mL) before transfusion and increased to nearly normal levels (204.4±24.8 pg/mL) after PLT administration. In parallel, the sCD40L release capacity per PLT showed no significant difference between controls and patients with thrombocytopenia before transfusion (33.3±2.6 and 29.3±4.6 ag/PLT, respectively) but was significantly reduced after PLT transfusion (22.4±2.7 compared to 29.3±4.6 ag/PLT). CONCLUSIONS In patients with thrombocytopenia, sCD40L levels were clearly influenced by PLT transfusions: PLT administration led to a normalization of sCD40L plasma concentration. Nevertheless, adverse transfusion reactions did not occur in these patients. The sCD40L release capacity was enhanced by PLT administration dependent on the increase in the amount of PLT count.
Collapse
|
55
|
|
56
|
Wenzel F, Günther W, Baertl A, Lasshofer R, Rox J, Fischer JC, Giers G. Comparison of soluble CD40L concentrations and release capacities in apheresis and prestorage pooled platelet concentrates. Clin Hemorheol Microcirc 2011; 47:269-78. [PMID: 21654056 DOI: 10.3233/ch-2011-1407] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
INTRODUCTION Soluble CD40L (sCD40L) is expressed by platelets and is involved in the stabilization of arterial thrombi. Additionally, it was shown that sCD40L accumulation occurred in stored blood products triggering adverse transfusion reactions like TRALI. To study the influence of the preparation technique on sCD40L accumulation and platelet function we examined CD40L concentrations in prestorage pooled platelet concentrates compared to apheresis products. In addition, sCD40L release capacity was determined as a marker for platelet viability. MATERIAL AND METHODS sCD40L concentrations were determined in prestorage pooled platelet concentrates (n = 8) and in platelet apheresis concentrates (n = 8) before and after platelet stimulation (recalcification and clot formation) at day 1, 3 and 5 under routine storage conditions. sCD40L concentrations were determined by a commercially available ELISA kit. RESULTS sCD40L concentrations in storage medium increased over time in prestorage pooled platelet concentrates (from 1,185 pg/mL ± 87 pg/mL at day 1 to 4,464 pg/mL ± 212 pg/mL at day 5) as well as in apheresis products (from 581 pg/mL ± 124 pg/mL at day 1 to 2,718 pg/mL ± 154 pg/mL at day 5) in a hyperbolic manner. Recalcification and clot formation caused an increase in sCD40L concentrations (for example 3,842 pg/mL ± 769 pg/mL before platelet activation to 31,219 pg/mL ± 2,063 pg/mL after platelet activation at day 3), and we observed comparable release capacities for both preparation techniques, however, decreasing over storage time up to 50% (day 5) of the respective control value (day 1). CONCLUSIONS Amounts of sCD40L accumulation and release capacity during storage of platelet concentrates were dependent on storage duration, but showed no relevant differences regarding the preparation technique. After 5 days of storage, CD40L basal levels were increased, in contrast sCD40L release capacity was decreased. By recalcification and clot formation sCD40L release capacity could be easily induced and is assumed to be used as a marker for platelet viability.
Collapse
|
57
|
Wenzel F, Baertl A, Hohlfeld T, Zimmermann N, Weber AA, Lorenz H, Giers G. Determination of thromboxane formation, soluble CD40L release and thrombopoietin clearance in apheresis platelet concentrates. Platelets 2011; 23:150-6. [PMID: 21806498 DOI: 10.3109/09537104.2011.599897] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
All deleterious changes in platelet morphology, structure and function that occur in platelet concentrates (PC) during storage are titled as the 'platelet storage lesion'. No single in vitro test currently available is sufficient in assessing these changes of platelet quality. The release of soluble CD40 Ligand (sCD40L), the formation of thromboxane (TXB2) and the thrombopoietin (TPO) clearance reflect different aspects of platelet metabolism and activitiy, and were used to examine platelet quality in apheresis platelet products. At days 1, 3 and 5, in single-donor apheresis platelet products (n = 10) under routine storage conditions, sCD40L (measured by ELISA) and TXB2 (measured by RIA) were determined after platelet stimulation (recalcification and clot formation). TPO (measured by ELISA) was determined after an incubation time of 5 h at 37°C with platelet-rich plasma (adjusted initial TPO concentration of about 500 pg/mL). Results were related to a therapeutic unit (TU = 2 × 10(11) platelets). Immediately after platelet preparation, sCD40L release was 41 ± 7.6 ng/TU, TXB2 formation 1688 ± 374 ng/TU and TPO clearance 1.22 ± 0.32 ng/h/TU. At days 1, 3 and 5, sCD40L was reduced to 89 ± 7%, 71 ± 12% and 57 ± 9%, TXB2 release to 91 ± 6%, 74 ± 12% and 58 ± 9% and TPO clearance to 90 ± 15%, 84 ± 5% and 79 ± 10% of the respective control values. In conclusion, in single-donor apheresis PC, sCD40L release and TXB2 formation as well as TPO clearance by the platelets were dependent on storage duration and reduced to about 60% to 80% of the respective control values after a storage period for 5 days. These findings are in line with literature data, indicating that a loss of platelet functionality of about 30% will occur after 5 days of storage.
Collapse
|
58
|
Giers G, Wenzel F, Riethmacher R, Lorenz H, Tutschek B. Repeated intrauterine IgG infusions in foetal alloimmune thrombocytopenia do not increase foetal platelet counts. Vox Sang 2011; 99:348-53. [PMID: 20624268 DOI: 10.1111/j.1423-0410.2010.01367.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND AND OBJECTIVES Foetal alloimmune thrombocytopenia (FNAIT) is often treated transplacentally with maternally administered i.v. immunoglobulins, but not all foetuses show a consistent platelet increase during such treatment. MATERIALS AND METHODS We retrospectively analysed data from a cohort of ten foetuses with FNAIT treated by direct foetal immunoglobulin infusion. Foetal treatment was begun between 17 and 25 weeks and continued until 36 weeks with weekly cordocenteses and foetal immunoglobulin infusions. RESULTS While foetal IgG levels increased steadily during weekly IgG infusions, foetal platelet counts remained unchanged. CONCLUSION Our retrospective study presents a unique analysis of a historical cohort, contributing to the ongoing debate about the treatment of choice for foetal alloimmune thrombocytopenia.
Collapse
|
59
|
Wenzel F, Günther W, Rox JM, Fischer JC, Giers G. Soluble CD40 ligand in stem cell products of autologous donors. Transfusion 2011; 51:226-7. [PMID: 21219327 DOI: 10.1111/j.1537-2995.2010.02916.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
60
|
Fischer JC, Quenzel EM, Moog R, Wenzel F, Riethmacher R, Tutschek B, Giers G. Reducing costs in flow-cytometric counting of residual white blood cells in blood products: utilization of a single-platform bead-free flow-rate calibration method. Transfusion 2011; 51:1431-8. [PMID: 21214578 DOI: 10.1111/j.1537-2995.2010.02998.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Commercial flow-cytometric methods for counting residual white blood cells (rWBCs) in leukoreduced blood products use calibration beads for estimation of the measured sample volume. A bead-free flow-rate calibration method is developed and validated. STUDY DESIGN AND METHODS The analyzed volume was calculated by acquisition time (ACQ). Twenty-nine spiking series of red blood cell (RBC) or platelet (PLT) products were prepared containing levels ranging from 0.08 × 10(6) up to 2048 × 10(6) WBCs/L. Nearly WBC-free triple-leukofiltered RBCs or PLT concentrates (PCs) served as background. Propidium iodide (PI) was used to identify rWBCs. Five RBC series were compared against a commercially available kit (LeukoSure, Beckman Coulter). Routine capabilities were tested on 41 RBC and 92 PC samples of two independent transfusion services. RESULTS The lower detection limit in RBC was 0.08 × 10(6) rWBCs/L for ACQ and 0.16 for LeukoSure. Criteria for linearity, accuracy, and precision were fulfilled within the range of 0.5 × 10(6) to 512 × 10(6) WBCs/L. For PCs, all these criteria were fulfilled between 0.5 × 10(6) and 32 × 10(6) rWBCs/L (lower detection limit of 0.25) for PI. ACQ and LeukoSure agreed sufficiently (81%) when tested on routine RBCs or PCs. CONCLUSION A residual WBC count of fewer than 0.5 × 10(6) WBCs/L can be accurately counted using the ACQ approach at a total reagent cost of less than 0.5€ per sample.
Collapse
|
61
|
Filges I, Röthlisberger B, Blattner A, Boesch N, Demougin P, Wenzel F, Huber AR, Heinimann K, Weber P, Miny P. Deletion in Xp22.11: PTCHD1 is a candidate gene for X-linked intellectual disability with or without autism. Clin Genet 2010; 79:79-85. [PMID: 21091464 DOI: 10.1111/j.1399-0004.2010.01590.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Submicroscopic chromosomal anomalies play an important role in the aetiology of intellectual disability (ID) and have been shown to account for up to 10% of non-syndromic forms. We present a family with two affected boys compatible with X-linked inheritance of a phenotype of severe neurodevelopmental disorder co-segregating with a deletion in Xp22.11 exclusively containing the PTCHD1 gene. Although the exact function of this gene is unknown to date, the structural overlap of its encoded patched domain-containing protein 1, the transmembrane protein involved in the sonic hedgehog pathway, and its expression in human cortex and cerebellum as well as in mice and drosophila brain suggests a causative role of its nullisomy in the developmental phenotype of our family. Our findings support the recent notions that PTCHD1 may play a role in X-linked intellectual disability (XLID) and autism disorders.
Collapse
|
62
|
Wenzel F, Rox J, Reinboldt S, Weber AA, Giers G, Fischer J. Release of soluble CD40L by matrix metalloprotease-2 (MMP-2)-dependent shedding of platelets and its subsequent accumulation in stem cell products of autologous donors. J Stem Cells Regen Med 2010; 6:66-67. [PMID: 24693086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|
63
|
Wenzel F, Lasshofer R, Rox J, Fischer J, Giers G. Transient appearance of postoperative EDTA-dependent pseudothrombocytopenia in a patient after gastrectomy. Platelets 2010; 22:74-6. [PMID: 20942597 DOI: 10.3109/09537104.2010.516847] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia (EDTA-PTCP) is a well known phenomenon. Antiplatelet antibodies cause platelet clumping in EDTA anticoagulated blood samples, and blood count analysers calculate a spurious low platelet count. We describe a case of a transient appearance of EDTA-PTCP in a patient after gastrectomy. A 58-year-old man underwent partial gastrectomy in for gastric cancer. Preoperatively, his platelet count was in a normal range, and the surgical procedure was performed without bleeding complications. At day 10 after surgery the patient showed a low platelet count, which could be identified as EDTA-PTCP. The phenomenon disappeared in a following postoperative time interval of 2 months. In cases of recently occurring thrombocytopenias EDTA-PTCP should always be considered as a possible cause of low platelet count, in particular in cases of inconspicuous clinical findings. Appropriate laboratory analysis should be applied.
Collapse
|
64
|
Giers G, Riethmacher R, Wenzel F, Tutschek B. Die fetale/neonatale Alloimmun-Thrombozytopenie (FNAIT). Geburtshilfe Frauenheilkd 2010. [DOI: 10.1055/s-0030-1250068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
65
|
Reinboldt S, Wenzel F, Rauch BH, Hohlfeld T, Grandoch M, Fischer JW, Weber AA. Preliminary evidence for a matrix metalloproteinase-2 (MMP-2)-dependent shedding of soluble CD40 ligand (sCD40L) from activated platelets. Platelets 2010; 20:441-4. [PMID: 19811225 DOI: 10.1080/09537100903096684] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Platelets are the major source of soluble CD40 ligand (sCD40L) in the blood. It has been demonstrated that CD40L is cleaved from the surface of activated platelets to release sCD40L. However, the enzyme involved in sCD40L shedding has not been identified yet. Using a panel of pharmacological inhibitors of serine, cysteine, aspartate, or metalloproteinases, preliminary evidence is presented for the hypothesis that matrix metalloproteinase-2 (MMP-2) might be the protease, primarily responsible for CD40L cleavage from platelet surface.
Collapse
|
66
|
Giers G, Wenzel F, Stockschläder M, Riethmacher R, Lorenz H, Tutschek B. Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion. Haematologica 2010; 95:1921-6. [PMID: 20534698 DOI: 10.3324/haematol.2010.025106] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Different therapeutic approaches have been used in fetal-neonatal alloimmune thrombocytopenia, but many centers administer immunoglobulin G infusions to the pregnant woman. We studied the effect of maternal antenatal immunoglobulin infusions on fetal platelet counts in pregnancies with fetal alloimmune thrombocytopenia. DESIGN AND METHODS We retrospectively analyzed the clinical courses of fetuses with fetal alloimmune thrombocytopenia whose mothers were treated with immunoglobulin G infusions in a single center between 1999 and 2005. In a center-specific protocol, weekly maternal immunoglobulin G infusions were given to 25 pregnant women with previously affected neonates and four women with strong platelet antibodies, but no previous history of fetal alloimmune thrombocytopenia; before each infusion diagnostic fetal blood sampling was performed to determine fetal platelet counts and immunoglobulin G levels. RESULTS There were 30 fetuses with fetal alloimmune thrombocytopenia, confirmed by initial fetal blood sampling showing fetal platelet counts between 4×10(9)/L and 130×10(9)/L and antibody-coated fetal platelets using a glycoprotein specific assay. Despite weekly antenatal maternal immunoglobulin G infusions fetal platelet counts did not change significantly. Maternal and fetal immunoglobulin G levels, measured before every infusion, increased significantly with the number of maternal immunoglobulin G infusions. CONCLUSIONS In this group of fetuses with fetal alloimmune thrombocytopenia no consistent increase of fetal platelets was achieved as a result of regular maternal immunoglobulin G infusions.
Collapse
|
67
|
Giers G, Wenzel F, Fischer J, Stockschläder M, Riethmacher R, Lorenz H, Tutschek B. Retrospective comparison of maternal vs. HPA-matched donor platelets for treatment of fetal alloimmune thrombocytopenia. Vox Sang 2010; 98:423-30. [DOI: 10.1111/j.1423-0410.2009.01268.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
68
|
Wenzel F, Gruber W, Giers G. Alteration of serum thrombopoietin levels in patients with chronic hepatitis C under interferon therapy. Clin Hemorheol Microcirc 2010; 44:137-44. [DOI: 10.3233/ch-2010-1262] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
69
|
Wenzel F, Giers G. Identification of reduced serum thrombopoietin concentrations in patients with chronic hepatitis C undergoing an interferon therapy. Clin Chem Lab Med 2010; 48:1191-2. [DOI: 10.1515/cclm.2010.232] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
70
|
Zimmermann N, Kurt M, Winter J, Gams E, Wenzel F, Weber AA, Hohlfeld T. Aspirin-induced platelet inhibition in patients undergoing cardiac surgery. Platelets 2009; 18:528-34. [DOI: 10.1080/09537100701321250] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
71
|
Zimmermann N, Kurt M, Winter J, Gams E, Wenzel F, Hohlfeld T. Detection and duration of aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2008; 135:947-8. [DOI: 10.1016/j.jtcvs.2007.11.033] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2007] [Accepted: 11/15/2007] [Indexed: 10/22/2022]
|
72
|
Adamzik M, Bachmann HS, Görlinger K, Grandoch M, Leineweber K, Müller-Beißenhirtz H, Wenzel F, Naber C, Weber AA. Methoden zur Messung der Azetylsalizylsäure- bzw. Clopidogrelresistenz. Hamostaseologie 2008. [DOI: 10.1055/s-0037-1616924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
ZusammenfassungBasierend auf der Prämisse, wonach eine so genannte Resistenz gegenüber Thrombozytenfunktionshemmern vorliegt, wenn das Pharmakon den für die klinische Wirksamkeit entscheidenden pharmakodynamischen Effekt nicht ausübt, sollten zur Evaluation der Wirkung von Thrombozytenfunktionshemmern Laborteste eingesetzt werden, die den pharmakodynamischen Effekt möglichst direkt erfassen.Für die Evaluation von Azetylsalizylsäurewirkungen scheint die Messung von Thromboxan B2 oder die der Arachidonsäure- induzierten Aggregation (Turbidimetrie oder Vollblutaggregometrie) angebracht. Für die Evaluation von Clopidogrelwirkungen scheint die Messung der VASP-Phosphorylierung (Durchflusszytometrie) oder die der ADPinduzierten Thrombozytenaggregation (Turbidimetrie oder Vollblutaggregometrie) sinnvoll.
Collapse
|
73
|
Weber AA, Adamzik M, Bachmann HS, Görlinger K, Grandoch M, Leineweber K, Müller-Beissenhirtz H, Wenzel F, Naber C. [Methods to evaluate aspirin and clopidogrel resistance]. Hamostaseologie 2008; 28:66-71. [PMID: 18278165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023] Open
Abstract
Based on the concept that the so-called resistance to anti-platelet drugs is meant to describe a phenomenon where the drug does not hit its direct pharmacodynamic target, assays, used to evaluated the effects of anti-platelet drugs, should as closely as possible measure the direct pharmacodynamic effect of a particular drug. Thus, for the detection of aspirin effects, thromboxane concentrations or arachidonic acid-induced responses (light aggregometry, whole-blood aggregometry) should be measured. For the detection of clopidogrel actions, VASP phosphorylation (flow cytometry) or ADP-induced responses (light aggregometry, whole blood aggregometry) should be analysed.
Collapse
|
74
|
Wenzel F, Baertl A, Zimmermann N, Hohlfeld T, Giers G, Oldenburg J, Assert R. Different behaviour of soluble CD40L concentrations can be reflected by variations of preanalytical conditions. Clin Hemorheol Microcirc 2008. [DOI: 10.3233/ch-2008-1112] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
75
|
Wenzel F, Baertl A, Zimmermann N, Hohlfeld T, Giers G, Oldenburg J, Assert R. Different behaviour of soluble CD40L concentrations can be reflected by variations of preanalytical conditions. Clin Hemorheol Microcirc 2008; 39:417-422. [PMID: 18503154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
INTRODUCTION Biomarkers reflecting an inflammatory or immunological response are increasingly offered to improve the risk stratification of patients. For example, current evidence suggests that soluble CD40 ligand (sCD40L) is elevated in patients with acute coronary syndrome. But only a few data are available to evaluate the influence of preanalytic conditions on sCD40L values. METHODS Blood samples of seven healthy blood donors were collected in tubes without additives and in EDTA- or citrate-filled tubes at various storage conditions. Platelet count was modified by serum dilution, and sCD40L was measured in platelet-rich-plasma and in whole blood. sCD40L levels were determined by an commercially available ELISA-Kit. RESULTS Immediately after blood sample assessment, sCD40L levels in serum samples were elevated (1258+/-820 pg/ml) compared to EDTA (64+/-32 pg/ml) and citrate (60+/-8.5 pg/ml) values. Additionally, sCD40L levels were dependent on storage duration. After platelet activation, sCD40L levels were significantly increased to 8278+/-2453 pg/ml and were significantly correlated to platelet count (r=0.96). CONCLUSIONS Soluble CD40L levels were clearly influenced by preanalytical conditions and were dependent on storage duration, sample technique and platelet count. These influences should be considered by the determination and evaluation of sCD40L concentrations.
Collapse
|